---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347907"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2026-08-13T11:40:44+00:00"
generated_at: "2026-08-13T11:45:20.212725+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MiNK Q2 2026 net loss $3.1M, cash $8.8M; Phase 2 ALI data positive

## Summary
- Net loss $3.1M ($0.62/share) vs $4.2M ($1.06) in Q2 2025; six-month loss $5.9M vs $7.0M.
- Cash $8.8M at June 30, 2026, down from $9.5M at March 31 and $13.4M at Dec 31, 2025.
- Randomized Phase 2 (C-1300-02) in acute lung injury: first patients alive at Day 28, improved oxygenation, infection control, ventilator/vasopressor liberation; no major SAEs.
- Established first paid international named-patient access program in Brazil via Orphan Drug Consulting for agenT-797.
- Data presented at MHSRS; U.S. expansion underway, more data expected early 2027.

## SEC filing metadata
- accession: 0001193125-26-347907
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2026-08-13T11:40:44+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/0001193125-26-347907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000119312526347907/inkt-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347907
- JSON: https://secwatch.observer/filing/0001193125-26-347907.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.